Parent Project Muscular Dystrophy (PPMD) will host a Congressional Briefing entitled Realizing the Promise of Patient-Focused Drug Development at noon in the Capitol Visitor Center (SVC 202). The goal of this briefing is to highlight the tremendous momentum within the drug development pipeline that has directly resulted from Patient Focused Drug Development (PFDD) policies and federal agency activities. Duchenne community stakeholders, including patient community members involved in clinical trials, industry representatives, clinicians, and patients receiving access to the first approved Duchenne therapies, will provide examples as to how the innovations resulting from PFDD pathways have impacted drug development, regulatory reviews, and access to new drug therapies.
Back to All Events
Earlier Event: March 5Caring in Crisis: The Critical Role of Hospitals During Disasters